Stem cell specialist ReNeuron Group Plc (LON:RENE) has been awarded a £1.8mln grant from Innovate UK, the UK government’s tech arm, to develop its commercial cell therapy manufacturing skills.
Awarded under "Cell2Sell”, Innovate UK's Cell & Gene Therapies Industrial Manufacture grant scheme, the money will fund a collaborative programme of work to be undertaken by ReNeuron, as lead participant, and the Cell & Gene Therapy Catapult.
WATCH: ReNeuron CFO 'very pleased' to be awarded £1.8mln grant
The grant will fund key process development activities relating to larger scale commercial manufacture of ReNeuron's cell therapy candidates.
These include the development of robust manufacturing processes utilising next generation technology and techniques to produce therapeutic candidates on a commercial scale, said the company.
Sharon Grimster, ReNeuron’s General Manager, Wales, said she was delighted with the award.
“It enables us to further pursue and optimise our cell therapy manufacturing processes as our therapeutic programmes get closer to market.”